<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13947">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925338</url>
  </required_header>
  <id_info>
    <org_study_id>C1231004</org_study_id>
    <secondary_id>REFLECT</secondary_id>
    <nct_id>NCT02925338</nct_id>
  </id_info>
  <brief_title>National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life</brief_title>
  <acronym>ReFLECT</acronym>
  <official_title>Observatoire National D'Utilisation D'Inflectra™ En Vie Réelle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      National, prospective, multicentre observational study designed for eligible patients
      treated with Inflectra.

      Its objectives are to describe under real conditions of use, the profile of patients treated
      with Inflectra and the response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Anticipated">September 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients without treatment failure during the 2 year follow-up period</measure>
    <time_frame>Baseline through Month 24</time_frame>
    <description>Response to treatment will be described indirectly and expressed as percentage of patients without treatment failure during the 2 year follow up period
o Treatment failure = definitive discontinuation of InflectraTM for &quot;Loss of efficacy&quot; or &quot;Intolerance&quot;, or AE related to InflectraTM resulting in death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average time between diagnosis and inclusion.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Average Duration of previous biotherapies</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean weight of patients enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean age of patients enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average time between diagnosis and 1st Inflectra infusion</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean dose administered (in mg)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>osology of infusion No.1+⋯+Posology of infusion No.X/Number of infusions listed during period in question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose (mg)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Cumulative dose = Sum of doses during period in question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean infusion time (minutes)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Duration of infusion No.1 +⋯+Duration of infusion No.X /Number of infusions times listed during period in question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean post-infusion monitoring time at hospital (minutes)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Duration of monitoring No.1 +⋯+Duration of monitoring No.X/Number of monitoring times listed during period in question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time between infusions (weeks)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>∑_(i=1)^x〖(Date of infusion No.i-Date of infusion No.(i-1))/7〗/Number of infusions listed during period in question -1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute variation of mean global disease assessment compared with baseline</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Mean global disease assessment score during period in question - Global disease assessment score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute variation of mean fatigue score compared with baseline</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Mean fatigue score during period in question - Fatigue score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute variation of mean of each activity index score compared with baseline</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Mean activity index score during period in question - activity index score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute variation of endoscopic score compared with baseline</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Endoscopic score at visit X - Endoscopic score at baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Crohn Desease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients treated with Inflectra</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QOL questionaire</intervention_name>
    <description>Health assessment questionnaire disability index for rheumatoide polyarthritis questionnair</description>
    <arm_group_label>Patients treated with Inflectra</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients treated with Inflectra™ regardless of treatment phase in one of the
        following indications consistent with the SPC: Crohn's Disease, ulcerative colitis,
        rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

        Paediatric patients (children and adolescents between 6 and 17 years old) treated with
        Inflectra™, regardless of treatment phase from the time when Inflectra™ is prescribed in
        accordance with the indications listed in the SPC Crohn's Disease or ulcerative colitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients treated with Inflectra™ regardless of treatment phase in one of the
             following indications consistent with the SPC: Crohn's Disease, ulcerative colitis,
             rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

          -  Paediatric patients (children and adolescents between 6 and 17 years old) treated
             with Inflectra™, regardless of treatment phase from the time when Inflectra™ is
             prescribed in accordance with the indications listed in the SPC Crohn's Disease or
             ulcerative colitis Patients (or their legal representatives) who have received
             information (verbally and in writing) about the study and agreed to take part in it.

          -  Patients who have given their agreement for their clinical data and their medical
             file to be accessed by signing the information leaflet.

        Exclusion Criteria:

          -  Patients who refuse access to their medical file for collection of: their medical
             data

          -  Patients not treated with Inflectra™.

          -  Patients treated with Inflectra™ for psoriasis.

          -  Patients with a past history of hypersensitivity to infliximab, to other murine
             proteins or to one of the excipients in Inflectra™.

          -  Patients with tuberculosis or any other severe infection such as sepsis, abscess or
             opportunistic infection .

          -  Patients with moderate to severe heart failure (NYHA III/IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand Cedex</city>
        <state>Puy-de-dôme</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon, Service de Gastrologie</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Carcassonne, Service de Rhumatologie</name>
      <address>
        <city>Carcassonne</city>
        <zip>11000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Estaing, Service de Medicine Interne</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Sud</name>
      <address>
        <city>Echirolles</city>
        <zip>38434</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1231004&amp;StudyName=Observatoire+National+D%E2%80%99utilisation+D%E2%80%99inflectra%E2%84%A2+En+Vie+R%C3%A9elle.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>October 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
